Evidence map›Paper›PMID 41157909›Full record

ArticleInternational journal of geriatric psychiatry2025

Development of the Clinical Insight Questionnaire: A Novel Clinical Tool for the Assessment of Insight Into Cognitive Symptoms and Everyday Functioning in People With Neurodegeneration.

Catherine Pennington, Harriet Ball, Peter Connelly, Elizabeth Coulthard, Gordon Duncan, Chineze Ivenso, Tobias Langheinrich, Vivek Pattan, Terence Quinn, Karen Ritchie and 2 more

Abstract read
In one paragraph

Article in International journal of geriatric psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Catherine PenningtonUniversity of Edinburgh & NHS Lothian, Edinburgh, UK.ORCID https://orcid.org/0000-0003-0675-9619
Harriet BallUniversity of Bristol, Bristol, UK.
Peter ConnellyNeuroprogressive Disorders and Dementia Research Network, Dundee, UK.
Elizabeth CoulthardUniversity of Bristol, Bristol, UK.
Gordon DuncanUniversity of Edinburgh & NHS Lothian, Edinburgh, UK.
Chineze IvensoAneurin Bevan University Health Board, Glasgow, UK.
Tobias LangheinrichGreater Manchester Neuroscience Centre, Salford, UK.ORCID https://orcid.org/0000-0002-4714-8657
Vivek PattanNHS Forth Valley, Larbert, UK.
Terence QuinnUniversity of Glasgow, Glasgow, UK.ORCID https://orcid.org/0000-0003-1401-0181
Karen RitchieFrench Institute of Health and Medical Research, Montpellier, France.
Craig RitchieScottish Brain Sciences, Edinburgh, UK.
Tom RussUniversity of Edinburgh & NHS Lothian, Edinburgh, UK.

Funding

Chief Scientist Office, Scottish Government Health and Social Care Directorate
6 · The paper itself

Abstract

objectivesAltered insight into cognitive symptoms and diagnosis is a common feature of neurodegeneration, and can adversely impact on quality of life and ability to access medical care. Affected individuals can lose awareness of their symptoms and therefore decline to engage with medical assessment and treatment. Assessing insight is difficult, and there is a lack of short, easily administered clinical assessment tools. The aim of this study was to develop and evaluate the feasibility of a novel insight assessment questionnaire (The Clinical Insight Questionnaire, CLIQ) which can be independently completed by adults with a range of cognitive abilities.

methodsA discrepancy score approach was used to evaluate insight. A novel questionnaire targeting the domains of memory, personality and social behaviour, executive function, language, and activities of daily living was devised using the Delphi approach and public feedback. Participant and informant mirror versions of each item were written. The discrepancy between participant and informant scores provides an overall insight score. 12 UK based experts in cognitive disorder diagnosis and assessment were invited to review potential questionnaire items, as was a PPI group. A feasibility study was conducted where people with mild memory or thinking symptoms and an informant completed the questionnaire and the Montreal Cognitive Assessment.

resultsFollowing an iterative process using the expert Delphi group and public feedback, 20 final questionnaire items were selected from an initial pool of 30 items. 21 people with mild cognitive symptoms but no formally diagnosed cognitive disorder (median MoCA score 24.5) participated in feasibility testing. The mean discrepancy score was 1.14, close to the ideal score of zero. No participants found the assessment upsetting or too long, and 81% rated the questions as easy to understand.

conclusionsThe Clinical Insight Questionnaire (CLIQ) is a novel clinical tool for the assessment of insight in people with mild to moderate neurodegeneration. In feasibility testing it was quick and easy for people with mild cognitive symptoms and informants to self-complete. Initial feasibility testing showed very promising findings for usability and acceptability, and a full validation study is now in progress.

Indexed as

Activities of Daily LivingCognitive DysfunctionNeurodegenerative DiseasesAdultAgedAged, 80 and overDelphi TechniqueFeasibility StudiesFemaleHumansMaleMiddle AgedNeuropsychological TestsSurveys and Questionnairesanosognosiadementiainsightmild cognitive impairmentneurodegenerationsymptom awareness

Identifiers

PMID41157909
PMCPMC12569398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.